Neuralstem, Inc.

University of California

Neuralstem Biopharmaceuticals Ltd.

Cns Stem Cell Technology, Inc.

Alto Neuroscience, Inc.

Lin, Shinn-zong

Shyu, Woei-cherng

Wang, Hsiao-jung

Kelleher-andersson, Judith

Johe, Karl K.

Karl K Johe

Judith Kelleher-Andersson

Thomas Hazel

Martin Marsala

Osamu Kakinohana

Renji Yang

Shinn-Zong Lin

Woei-Cherng Shyu

David C Bowen

Hsiao-Jung Wang

Thomas G Hazel

Jun Yan

Vassilis Koliatsos

Osamu Kakinohama

Paul J Reier

Margaret J Velardo

The present disclosure provides a human neural stem cell comprising an exogenous polynucleotide coding for a growth factor such as IGF-1. Also disclosed are methods of using the human neural stem cells for the treatment of neurodegenerative diseases or disorders including, for example, ALS.

Stable neural stem cells comprising an exogenous polynucleotide coding for a growth factor and methods of use thereof

Motor skill deficits and cognitive deficits associated with stroke and secondary neuronal cell death are ameliorated by treatment with pharmaceutically acceptable salts of 2-amino substituted nicotinamides.

Amelioration of certain deficiencies due to stroke

Methods for treating non-systemic deficiencies associated with diabetes using 2-amino substituted nicotinamides or their pharmaceutically acceptable salts.

Amelioration of neural deficits associated with diabetes

The invention relates generally to methods of treating spasticity, rigidity, or muscular hyperactivity conditions by introducing a portion of an expanded population of neural stem cells into an area of a recipient spinal cord.

Methods of treating neurodegenerative conditions

Methods of treating ischemic spasticity

Although it is known that certain benzylpiperazine-aminopyridines or open chain forms thereof are effective in stimulating neural growth in in vitro tests, it has now been surprisingly found that administering these compounds in a dosage range of 10 mg/day-130 mg/day over 25-35 days is effective in treating Major Depressive Disorder (MDD) such that statistically significant results can be obtained with samples of only six subjects.

Protocols for treatment of major depressive disorder (MDD)

The present disclosure provides methods for the treatment of neurological diseases/disorders using neural stem cells (NSCs) obtained from a spinal cord tissue. The methods may include the use of a NSC population to treat a neurological disease/disorder of the brain. Such methods may include introducing exogenously cultured and expanded NSCs into the brain, which differentiate into neurons capable of integrating in vivo into the brain tissue in a sufficient manner to ameliorate the symptoms associated with the neurological disease/disorder.

Methods for treating and/or reversing neurodegenerative diseases and/or disorders

A systematic and efficient method for establishing stable neural stem cell lines and neuronal progenitor lines is described. The resulting cell lines provide robust, simple, and reproducible cultures of human and other mammalian neurons in commercially useful mass quantities while maintaining normal karyotypes and normal neuronal phenotypes.

Stable neural stem cell lines

Compositions containing neurogenic agents for inhibition of neuron death and inducing proliferation of neural cells are disclosed.

Compositions to effect neuronal growth

Methods of treating amyotrophic lateral sclerosis (ALS)

A method for discovering neurogenic drugs is revealed. The method allows for systematic screening of test agents such as libraries of compounds. The method consists of exposing test agents to cultures of differentiating neural progenitor cells and measuring their effects on increasing the overall cell number and/or the number of neurons.

Method for screening neurogenic agents

Growing community of inventors

Potomac, MD, United States of America

Karl K Johe